- Home
- ACET vs INCR Comparison
ACET vs INCR Comparison
Compare ACET & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- INCR
- Stock Information
- Founded
- ACET 1947
- INCR 1994
- Country
- ACET United States
- INCR Israel
- Employees
- ACET N/A
- INCR N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- INCR Biotechnology: Pharmaceutical Preparations
- Sector
- ACET Health Care
- INCR Health Care
- Exchange
- ACET Nasdaq
- INCR Nasdaq
- Market Cap
- ACET 70.3M
- INCR 76.7M
- IPO Year
- ACET N/A
- INCR N/A
- Fundamental
- Price
- ACET $0.66
- INCR $1.29
- Analyst Decision
- ACET Buy
- INCR
- Analyst Count
- ACET 6
- INCR 0
- Target Price
- ACET $6.00
- INCR N/A
- AVG Volume (30 Days)
- ACET 312.0K
- INCR 11.3K
- Earning Date
- ACET 03-06-2025
- INCR 04-15-2025
- Dividend Yield
- ACET N/A
- INCR N/A
- EPS Growth
- ACET N/A
- INCR N/A
- EPS
- ACET N/A
- INCR N/A
- Revenue
- ACET N/A
- INCR $72,420,918.00
- Revenue This Year
- ACET N/A
- INCR N/A
- Revenue Next Year
- ACET N/A
- INCR $39.30
- P/E Ratio
- ACET N/A
- INCR N/A
- Revenue Growth
- ACET N/A
- INCR N/A
- 52 Week Low
- ACET $0.67
- INCR $1.17
- 52 Week High
- ACET $2.40
- INCR $3.72
- Technical
- Relative Strength Index (RSI)
- ACET 34.86
- INCR 25.95
- Support Level
- ACET $0.74
- INCR $1.36
- Resistance Level
- ACET $0.91
- INCR $1.49
- Average True Range (ATR)
- ACET 0.06
- INCR 0.06
- MACD
- ACET -0.01
- INCR -0.01
- Stochastic Oscillator
- ACET 4.82
- INCR 3.48
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.